Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571

被引：0
|
作者：
Chiu, A
Silver, R
Rosamillia, M
Chadburn, A
机构：
[1] Cornell Univ, Weill Med Coll, New York, NY USA
[2] Novartis Pharmaceut AG, Basel, Switzerland
来源：
MODERN PATHOLOGY | 2001年 / 14卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
934
引用
收藏
页码：159A / 159A
页数：1
相关论文
共 50 条
  • [1] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    LABORATORY INVESTIGATION, 2001, 81 (01) : 159A - 159A
  • [2] Treatment of chronic myeloid leukemia (CML) with STI571 in patients age ≥60 years.
    Cortes, J
    Talpaz, M
    O'Brien, SM
    Manero, G
    Thomas, D
    Faderl, S
    Capdeville, R
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 256B - 256B
  • [3] Effects of STI571 on bone marrow morphology in patients with CML: A longitudinal study of 49 patients.
    Hasserjian, RP
    Boecklin, F
    Parker, S
    Grover, S
    Dhar, S
    Zaiac, M
    Olavarria, E
    Lampert, IA
    Apperley, J
    Goldman, JM
    BLOOD, 2000, 96 (11) : 735A - 735A
  • [4] Importance of bone marrow biopsy in evaluating the responses to STI-571 in accelerated and blast phases of chronic myeloid leukemia (CML).
    Silver, RT
    Chadburn, A
    Feldman, E
    Schuster, M
    Godwin, J
    Berk, G
    Rosamilia, M
    BLOOD, 2000, 96 (11) : 257B - 257B
  • [5] Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
    Kvasnicka, HM
    Thiele, J
    Staib, P
    Schmitt-Graeff, A
    Griesshammer, M
    Klose, J
    Engels, K
    Kriener, S
    BLOOD, 2004, 103 (09) : 3549 - 3551
  • [6] Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia
    Gorre, ME
    Sawyers, CL
    CURRENT OPINION IN HEMATOLOGY, 2002, 9 (04) : 303 - 307
  • [7] Correlation of bone marrow morphologic features with the presence of the Philadelphia chromosome in STI571-treated, chronic phase chronic myeloid leukemia (CML)
    Schlette, E
    Onciu, M
    Giles, F
    Lai, R
    MODERN PATHOLOGY, 2002, 15 (01) : 262A - 262A
  • [8] Minimal residual disease (MRD) monitoring in chronic myelogenous leukemia (CML) patients treated with STI571 (Glivec®)
    Roche-Lestienne, C
    Grardel-Duflos, N
    Cornu-Soenen, V
    Laï, JL
    Roumier, C
    Berthaud, P
    Cosson, A
    Facon, T
    Preudhomme, C
    LEUKEMIA, 2001, 15 (12) : 2023 - 2023
  • [9] Treatment with STI571 (Novartis®) in chronic myeloid leukemia (CML):: Unexpected hematological findings in a series of 26 patients.
    Meunier, V
    Giraudier, S
    Van den Akker, J
    Perot, C
    Jouault, H
    Caron-Servan, B
    Robin, V
    Tulliez, M
    Imbert, M
    BLOOD, 2001, 98 (11) : 263B - 263B
  • [10] Comparison of the effects of STI571 (GLEEVEC) versus interferon-α on the bone marrow of CML patients
    Hasserjian, RP
    Chase, A
    Olavarria, E
    Lampert, I
    Henry, K
    Apperley, JF
    Goldman, JM
    MODERN PATHOLOGY, 2002, 15 (01) : 243A - 244A
12345